Omico’s Post

Did you know according to the World Health Organization’s cancer agency, the International Agency for Research on Cancer (IARC), lung cancer was the most frequently diagnosed cancer in 2022, accounting for nearly 2.5 million new cases, or 12.4% of all cancers worldwide? On this World Lung Cancer Day, we shine light on advancements in diagnostics that aid in the fight against lung cancer. CEA levels measured by Beckman Coulter Diagnostics' Access Immunoassay Analyzers aids in the management of cancer patients in whom changing CEA concentrations have been observed. Explore our immunoassay analyzers for early detection, effective management, and closing the care gap ➡️ https://bit.ly/3y8S1uQ #WorldLungCancerDay #CEAAssay #Immunoassay #CloseTheCareGap

Today, we acknowledge World Cancer Day, a global initiative led by the Union for International Cancer Awareness. According to https://buff.ly/3uCISZn: -10 million people die each year from cancer. -70% of cancer deaths occur in low-to middle income countries. -Less than 30% of low-income countries have cancer treatment services available. As the field of immuno-oncology progresses, we expect that improvement in diagnosis will provide an opportunity to treat cancer earlier and more effectively and that the availability of these treatments is accessible to all. We are committed to working on developing our immuno-oncology therapies and making a difference. #cancer #oncology #immunooncology #worldcancerday #ImaginAb

Did you know according to the World Health Organization’s cancer agency, the International Agency for Research on Cancer (IARC), lung cancer was the most frequently diagnosed cancer in 2022, accounting for nearly 2.5 million new cases, or 12.4% of all cancers worldwide? On this World Lung Cancer Day, we shine light on advancements in diagnostics that aid in the fight against lung cancer. CEA levels measured by Beckman Coulter Diagnostics' Access Immunoassay Analyzers aids in the management of cancer patients in whom changing CEA concentrations have been observed. Explore our immunoassay analyzers for early detection, effective management, and closing the care gap ➡️ https://bit.ly/3y8S1uQ #WorldLungCancerDay #CEAAssay #Immunoassay #CloseTheCareGap

NEWS: 'Lung cancer is the deadliest of all cancers, and screening could save many lives − if more people could access it' Informative piece in The Conversation US by pulmonologist Nina Thomas who specializes in screening and diagnosing lung cancer. 'Between 2015 and 2019, survival rates for lung cancer have improved by 22%, in part because of an increase in earlier diagnosis. Most patients with early-stage lung cancer, however, have no symptoms and aren’t diagnosed until they reach more advanced stages that are harder to treat, underlining the need for effective lung cancer screening.' Read the full article here: https://lnkd.in/e6icFEn4 #screening #lungcancerscreening #LungCancerEurope #LuCE #LCSM #cancerscreening

#WorldCancerResearchDay is September 24, a day to raise awareness about the importance of innovative research in the fight against cancer worldwide.  At Affimed, our research is focused on harnessing the immense power of the innate immune system to combat cancer by targeting and activating NK cells and macrophages with our innate cell engagers (ICE®). Our ongoing research includes studying acimtamig (AFM13) and AFM28 for their potential in treating certain blood cancers and AFM24 which we are studying for non-small cell lung cancer.  Find out more about our research at www.affimed.com #WorldCancerResearchDay #InnateImmunity #ImmunoOncology #AFMD #Immunotherapy #WhyWeFightCancer  

🎉 New Breakthrough in Ovarian Cancer Detection The Ovarian Cancer Institute (OCI) has developed a groundbreaking machine learning-based classifier that uses serum metabolic profiles to accurately identify ovarian cancer. With an impressive 93% accuracy, this innovative tool offers a new direction in early cancer detection. Key Highlights: 🔹 Predictive models accurately detect ovarian cancer. 🔹 Lipids predominate among the most informative metabolites. 🔹 Clinical tool provides a probabilistic assessment of cancer presence. Dr. Benedict B. Benigno, Founder and CEO  of OCI, states, "This method surpasses traditional tests in clinical informativeness and accuracy, representing a significant advancement in early ovarian cancer detection." Learn more about this significant advancement and read the full study: https://lnkd.in/eEdWadmv #OvarianCancer #CancerResearch #HealthcareInnovation #EarlyDetection #MachineLearning

Today, on Stand Up To Cancer Research Day, we’re reminded of the power of early detection. Oral cancer screenings are a vital tool in the fight against cancer, helping identify potential issues before they become life-threatening. By catching oral cancer early, we increase the chances of successful treatment and a healthier future. Join us in standing up to cancer by scheduling your screening today and supporting the ongoing research that saves lives! Stand Up To Cancer was created to accelerate groundbreaking cancer research that will get promising new cancer treatments to patients quickly. We won’t stop until every cancer patient is a long-term cancer survivor.#StandUpToCancer #OralHealthcare #OralCancerScreening #SU2C #WeKeepPeopleSmiling

A collaborative study between Childhood Cancer Canada and Colorectal Cancer Resource & Action Network: Do you have metastatic (stage IV)/advanced cancer? Are you a caregiver to someone with metastatic cancer? If so, we want to hear from you! @ccranorg is conducting a collaborative pan-tumor biomarker survey to address the challenges that patients face in accessing biomarker testing and comprehensive genomic profiling (CGP). The data gathered through this survey will be used to advocate for timely and equitable access to biomarker testing results, Comprehensive Genomic Profiling, and thereby precision medicines that may help improve patient outcomes in Canada. Please help us ensure your voice is heard by completing the survey before April 26th, 2024: https://lnkd.in/dyrBzQMA #CCRAN #CancerSurvery #Cancercanada #CGP #Biomarkers #PrecisionMedicine

The side effects of cancer treatment are often cited as the more harrowing part of fighting the disease. But thanks to the success of a clinical trial at MUSC Hollings Cancer Center, and a $3.2 million grant from the National Cancer Institute, treatment for certain cancers may come with fewer complications. Brian Hess, M.D., and Shikhar Mehrotra, Ph.D., have partnered on a project to develop “purified” CAR-T cells to treat people with certain B-cell non-Hodgkin lymphomas who have already tried other therapies. CAR-T cell therapy is FDA-approved for certain types of blood cancer, but the Hollings trial is testing a new patented variation that the researchers hope will have longer-lasting results with fewer side effects. #ChangingWhatsPossible Read more: https://lnkd.in/ewBjKec8 #CancerResearch #cancer

Today is World Lung Cancer Day, a day dedicated to raising awareness about the impact of lung cancer. In honor of this important day, we want to highlight a recent study done by AstraZeneca and the Cleveland Clinic using the CancerLinQ Discovery database. The researchers investigated the prevalence of EGFR mutations in early-stage non-small-cell lung cancer (NSCLC) patients and the treatments they received in routine clinical practice. EGFR mutations can impact treatment decisions, especially for patients with stage IB–IIIA NSCLC. Findings show that only 21.6% of patients underwent EGFR mutation testing, highlighting the importance of testing for personalized treatment plans. Learn more: https://hubs.ly/Q02JKNzN0 #LungCancerResearch #EGFRmutations #PersonalizedMedicine #WLCD24 #WorldLungCancerDay